Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, Boston Children's Hospital Collaborate to Find Pain Syndrome Genes

NEW YORK (GenomeWeb) – Amgen and Boston Children's Hospital announced yesterday that they have entered into a one-year research collaboration aimed at identifying novel genes underlying anomalies of pain sensitivity, and validating the genetic findings as possible targets for therapeutics.

The partners will combine Amgen's expertise in genetic target identification and validation with access to Boston Children's Division of Pain Medicine to identify patients with abnormal pain conditions. The hospital's Division of Pain Medicine treats patients with rare conditions that make them strikingly insensitive or hypersensitive to pain, or apt to experience pain spontaneously with no apparent stimulus.

As part of the collaboration, the teams will study patients with genetic disorders that diminish pain sensitivity; erythromelalgia, a condition causing intense, burning pain in the extremities; paroxysmal extreme pain disorder, a condition characterized by skin flushing and severe pain attacks in various parts of the body; and hereditary sensory and autonomic neuropathy.

"Traditional approaches to analgesic drug discovery have been pretty disappointing during the past 20 years," Charles Berde, chief of the Division of Pain Medicine, said in a statement. "The most innovative biotech companies have realized that they need to pursue new directions for drug discovery. Patients with unusual patterns of increased or decreased pain responsiveness can offer important clues in this pursuit."

John Dunlop, vice president of neuroscience research at Amgen, added that the partnership emphasizes his company's investment in "pursuing targets that have clear genetic support," and noted that the collaboration will focus especially on finding treatments for pain that are non-addictive.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.